Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.70 |
| ▸ | FNTA | P49354 | 8/20 | 0.59 |
| ▸ | FNTB | P49356 | 8/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | GRIA4 | P48058 | 6/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16792031 | 0.86 | FNTA (0.59) | PIK3CAFNTAFNTBKMT2AGRIA4 | |
| SCHEMBL8006300 | 0.82 | PIK3CA (1.00) | PIK3CAFNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16792125 | 0.78 | GRIA4 (0.78) | PIK3CAFNTAFNTBKMT2AGRIA4 | |
| SCHEMBL3134093 | 0.77 | GRIA4 (0.65) | PIK3CAFNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16792035 | 0.76 | PIK3CA (0.43) | PIK3CAFNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16792274 | 0.75 | FNTA (1.00) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL10652875 | 0.75 | GRIA4 (0.74) | PIK3CAFNTAFNTBKMT2AGRIA4 | |
| SCHEMBL10238640 | 0.73 | FNTA (0.65) | PIK3CAFNTAFNTBKMT2AGRIA4 | |
| SCHEMBL3403807 | 0.73 | PIK3CA (0.78) | PIK3CAKMT2AGRIA4GRIA2MTOR | |
| SCHEMBL7506651 | 0.73 | FNTA (0.74) | FNTAFNTBKMT2AGRIA4GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160375041-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | TABACZYNSKI DAVID A (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160303146-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | TABACZYNSKI DAVID A (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375041-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | GGPS1, FDPS, COASY | PIK3CA 131/4885FNTA 4/4885FNTB 15/4885 |
| US-20160303146-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | GGPS1, FDPS, COASY | PIK3CA 202/4885FNTA 4/4885FNTB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.